Myogenic Potential of Extraocular Muscle Satellite Cells
Myogenic Potential of Extraocular Muscle Satellite Cells
批准号:
7586961
负责人:
LINDA K. MCLOON
金额:
$18.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-01 至 2011-02-28
关键词:
AdultAgeAgingApoptosisApoptoticAtrophicAutologousBiological AssayBromodeoxyuridineCD34 geneCell DeathCell divisionCellsCellular biologyCoupledDataDenervationDevelopmentDiseaseDuchenne muscular dystrophyEnvironmentEyeGenesGeneticGoalsHematopoieticHeterozygoteIn VitroInjuryLabelLaboratoriesLaryngeal muscle structureLegLifeLimb structureModelingMorphologyMusMuscleMuscle CellsMuscle DevelopmentMuscle FibersMuscle satellite cellMuscular DystrophiesMyoblastsMyopathyNatural regenerationNeonatalNewborn InfantPECAM1 genePTPRC genePatientsPopulationProcessProliferatingPropertyResistanceRestSkeletal MuscleSomitesSourceTestingTissuesTransplantationUtrophinWorkbasecell typein vivoirradiationmdx mousemouse modelnerve supplynovel strategiesorbit muscleprecursor cellpreventprogenitorpublic health relevanceregenerativeresearch studysatellite cell
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The extraocular muscles (EOM) are spared in Duchenne muscular dystrophy patients (DMD) and continue to function after most skeletal muscles in the body have completely degenerated. The reason for this sparing in DMD is unknown. Unlike limb skeletal muscle, normal adult EOM retain a population of activated satellite cells, the regenerative cell in adult skeletal muscle. Satellite cells actively fuse into normal myofibers in the EOM throughout life, even in aging EOM, resulting in a continuous process of myofiber remodeling. The EOM and their satellite cells are extremely resilient to injury, denervation, disease, and aging, retaining normal morphology when limb muscle would normally atrophy. In addition, the early genes controlling EOM development are distinct from those that control somite development. We will test the hypothesis that this continuous remodeling is the process by which EOM are spared in DMD. We will examine 1) the rate of myogenic precursor cell turnover in two mouse models of DMD, the mdx and mdx/utrophin+/- (mdx/utrhet) mice, and 2) test whether inhibition of cell division in the EOM prevent their sparing in the two mouse models for DMD. The sparing of the EOM in DMD, aging, and injury and differences in the myogenic precursor cell populations in skeletal muscle suggest myogenic precursor cells (mpcs) within EOM may be significantly enriched or phenotypically distinct compared with adult limb muscle cells. There are 5-8 fold more myogenic precursor cells in adult EOM compared to limb. Additionally, mpcs from EOM are more resistant to apoptosis than similar cells from limb. We will test the hypothesis that continuous remodeling allows for EOM sparing in DMD by examining 1) the rate of myogenic precursor cell turnover in two mouse DMD models, the mdx and mdx/utrophin+/- heterozygote (mdx/utrhet) mice, and 2) whether inhibition of cell division by gamma irradiation of the EOM prevents sparing in the DMD models. Sparing of the EOM in DMD and differences in their mpcs suggest that the EOM mpcs may be significantly enriched or phenotypically distinct compared with adult limb mpcs. One population is increased; these cells are CD34+ and negative for Sca1, CD31, an endothelial lineage marker, CD45, an hematopoietic lineage marker, and negative for various satellite cell markers (EOMCD34). These EOMCD34 cells are present in the EOM and limb muscles of neonatal mice, but only maintained throughout adulthood in EOM. These cells are also present in the EOM of mdx and mdx/utrophin-/- mice. Our hypothesis is that this population of EOMCD34 cells enriched in adult EOM may be, at least in part, responsible for the sparing of EOM in DMD. We will test these hypotheses in two Specific Aims. Specific aim 1 asks: 1) is the rate of myofiber remodeling increased in the DMD mice models? 2) Does inhibition of cell division in adult EOM prevent sparing in the EOM of mdx/utrophin +/- heterozygote mice? We will isolate specific subpopulations of mononucleated cells from EOM and limb muscles and in specific aim 2 ask: 1) Are the mpcs more resistant to injury?2) Are the mpcs from EOM more multipotent than those from limb muscle? 3) Do the myogenic precursor cells from EOM have greater proliferative potential than those derived from limb skeletal muscle? The long term goal is to define and isolate a myogenic precursor cell type from EOM that has greater proliferative and survival potential compared with limb. These cells would be tested in a myoblast transfer model to determine their potential for use in the treatment of DMD. These may offer advantages over other cells, as autologous transplants would be possible. PUBLIC HEALTH RELEVANCE: The extraocular muscles (EOM) are spared in Duchenne muscular dystrophy (DMD), and the cause of this sparing is unknown. The unique ability of EOM to continuously remodel throughout life suggests that this ability may be responsible for this sparing. This may be due to an enriched myogenic precursor cell population within the EOM that has a greater ability to survive injury, aging and disease. While the eye muscles are spared in DMD, the rate of regeneration in the EOM is similar to that in the leg muscles of the mdx mouse model of DMD. We will attempt to demonstrate that muscle precursor cell division is responsible for sparing of the EOM by using irradiation to inhibit cell division. It is well known that the EOM survive injury better than limb muscle. This in turn suggests that muscle progenitors in EOM may be more robust and long-lived than those from limb muscles. If these hypotheses are true, ultimately we hope to exploit this by using identified myogenic precursor cells from EOM as a new source of donor cells in myoblast therapy in mice models of muscle injury and DMD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sex as a Factor in Normal Retinal Function and Schizophrenia
-
批准号:10447908
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2022
-
负责人:LINDA K. MCLOON
-
依托单位:
Sex as a Factor in Normal Retinal Function and Schizophrenia
-
批准号:10598084
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2022
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:10004626
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9328086
-
项目类别:
-
资助金额:$14.21万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9073028
-
项目类别:
-
资助金额:$14.06万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Training Program in Translational Vision Sciences
-
批准号:9762109
-
项目类别:
-
资助金额:$8.93万
-
财政年份:2016
-
负责人:LINDA K. MCLOON
-
依托单位:
Myogenic Potential of Extraocular Muscle Satellite Cells
-
批准号:7777277
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2009
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:10228548
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8511649
-
项目类别:
-
资助金额:$53.04万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6986087
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8004985
-
项目类别:
-
资助金额:$36.13万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:10414024
-
项目类别:
-
资助金额:$47.99万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6737351
-
项目类别:
-
资助金额:$35.73万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:9915913
-
项目类别:
-
资助金额:$49.48万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7747975
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7885074
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:8338294
-
项目类别:
-
资助金额:$55.16万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:6838760
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:7196097
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
Novel Immunotoxin and IGF Therapy for Strabismus
-
批准号:9920850
-
项目类别:
-
资助金额:$3.44万
-
财政年份:2004
-
负责人:LINDA K. MCLOON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: